Argus Boosts Johnson & Johnson Price Target to $355 After Earnings
ArchivedSingle Source|2 articles|1 sources|1 blocks
Detected: Updated: Analyzed:
NarrativeRadar Analysis·Reviewed by M. Reyes·AI-assisted, editorially supervised·Based on 2 articles from 1 sources
Argus has raised its stock price target for Johnson & Johnson to $355 following the company's recent earnings report. This adjustment reflects improved financial expectations for the healthcare giant, potentially influencing investor decisions and market valuations. The update may affect trading activity and confidence in Johnson & Johnson's stock performance.
Reported Facts
Observable data points shared across all narratives
- •Argus increased Johnson & Johnson's stock price target to $355 on April 15, 2026.
- •The price target raise followed Johnson & Johnson's latest earnings announcement.
- •Johnson & Johnson is a major player in the healthcare and pharmaceutical industry.
What Could Happen If...
- ▸If Johnson & Johnson delivers stronger-than-expected future earnings investor confidence could rise further, potentially driving the stock price above the new target.
Market Exposure
StocksJohnson & JohnsonUpward Pressure
The raised price target by Argus following positive earnings signals increased investor optimism about the stock's value.
This is not investment advice. Market exposure is based on conditional event analysis.
Source Coverage
FINANCE
2 articles
Signals
Single-block coverage
Related Events
▸Lattice Semiconductor stock price target raised to $110 from $80 at StifelArchived▸Beta Technologies upgraded at Jefferies on near-term growth catalystsArchived▸Argus upgrades Freeport-McMoRan stock rating to Buy on copper demandArchived▸UBS raises Target stock price target to $144 on turnaround urgencyArchived▸Oppenheimer raises Travel + Leisure stock price target on earnings beat